1 April 2010 in Nanomedicine: Nanotechnology, Biology and Medicine
1 April 2011 in Nanomedicine: Nanotechnology, Biology and Medicine
1 June 2019 in Colloids and Surfaces B: Biointerfaces
30 May 2017 in Current Pharmaceutical Design
Oral diseases like dental caries and periodontal disease are directly associated with the capability of bacteria to form biofilm. Periodontal diseases have been associated to anaerobic Gram-negative bacteria forming a subgingival plaque (Porphyromonas gingivalis, Actinobacillus, Prevotella and Fusobacterium). Biofilm is a complex bacterial community that is highly resistant to antibiotics and human immunity. Biofilm communities are the causative agents of biological developments such as dental caries, periodontitis, peri-implantitis and causing periodontal tissue breakdown. The review recapitulates the latest advancements in treatment of clinical biofilm infections and scientific investigations, while these novel anti-biofilm strategies are still in nascent phases of development, efforts dedicated to these technologies could ultimately lead to anti-biofilm therapies that are superior to the current antibiotic treatment. This paper provides a review of the literature focusing on the studies on biofilm in the oral cavity, formation of dental plaque biofilm, drug resistance of bacterial biofilm and the antibiofilm approaches as biofilm preventive agents in dentistry, and their mechanism of biofilm inhibition.
8 July 2016 in Artificial Cells, Nanomedicine, and Biotechnology
The purpose of the present study was to develop loteprednol etabonate (LE) loaded poly(d,l-lactide co-glycolide) (PLGA) nanoparticles (NPs) and study their penetration profile into the excised goat cornea. In the present study, LE loaded PLGA NPs were prepared by solvent evaporation with high speed homogenization method and the penetration profile was studied using confocal laser scanning microscopy (CLSM). Rhodamine (Rd) was used as a fluorescent marker to prepare Rd-LE–PLGA-NPs. The NPs were characterized for particle size, X-ray diffraction (XRD), differential scanning calorimetry (DSC), transmission electron microscopy (TEM), drug entrapment, and permeation profile. Intense fluorescence observed across the depths of goat corneal tissue suggested an improved penetration profile of NPs. The entrapment efficiency and mean diameter of the optimized formulation (F5) were found to be 96.31 ± 1.68% and 167.6 ± 0.37 nm, respectively. These findings indicate that LE loaded PLGA NPs may serve as a potential drug carrier for ocular administration in eye disease.
8 February 2013 in African Journal of Pharmacy and Pharmacology
Psoriasis is a chronic inflammatory skin disease portrayed by erythematous, papulosquamous lesions. It is characterized by excessive growth and aberrant differentiation of keratatinocytes. The conventional topical treatments that have been used in the past, such as coal tar and dithranol, have low efficacy, poor aesthetic and cosmetic appeal, leading to poor patient compliance while systemic therapies such as methotrexate, cyclosporine and acitretin produce significant side effects. In recent years, several novel carriers like liposomes, nanostructured lipid carriers (NLC), etc. have been used in psoriasis, with promising results. Small and relatively narrow size distribution with novel carriers permits site specific delivery to the skin, with improved drug solubilization of hydrophobic drugs and bioavailability. This review highlights the recent advancements in the field of novel carriers for topical applications of antipsoriatic active moieties and bioactives. Key words: Novel carriers, topical, antipsoriatic drugs, psoriasis, skin.